Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of VEL-101 in Healthy Volunteers
NCT05238493Phase 1Completed
- Sponsor
- Veloxis Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Jan 2023
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FR104 in kidney transplant rejection, sponsored by Veloxis Pharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events, Serious Treatment-Emergent Adverse Events and 3 more. Started Apr 2022; status: completed.
02
Drugs
FR104
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT05238493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238493.